

21. (New) A therapeutic compound according to claim 13, wherein said endogenous vascular or blood component protein is long-lived.

22. (New) A therapeutic compound according to claim 21, wherein said endogenous vascular or blood component protein comprises serum albumin.

A2
0992163-030301
2008-09-22
23. (New) A therapeutic compound according to claim 13, wherein said therapeutic compound comprises a chemotherapeutic agent, an antibiotic, an antihypertensive agent, an anti-coagulant, an analgesic, a hormone, an immunosuppressive or immunoregulatory agent, an enzyme, a vasoactive drug, an anti-inflammatory drug, an anti-histamine, a cardiovascular drug or an anti-proliferative drug.

24. (New) A pharmaceutical composition comprising a therapeutic compound according to claim 13 and a physiologically acceptable medium.

25. (New) A pharmaceutical composition according to claim 24, wherein said physiologically acceptable medium comprises one or more of the following: saline, aqueous glucose, alcohol, deionized water, and phosphate buffered saline, dimethylsulfoxide, and vegetable oil.

26. (New) A composition consisting essentially of a compound formulated in a physiologically acceptable medium, said compound comprising a therapeutic entity, an *in vivo*

A2

- SECRET**

32. (New) A composition according to claim 26, wherein said therapeutic entity is a synthetic peptide; said linking entity is from 6 to 15 atoms in length between said therapeutic entity and said chemically reactive group; and said chemically reactive group is N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or maleimide.

33. (New) A method of providing a therapeutic activity to a patient, said method comprising administering to said patient in a therapeutically effective amount a composition according to claim 26.

REMARKS

Claims 1-12 are cancelled. New claims 13-33 are added. New claims 13-33 find support at page 3, lines 7-9 and page 12, lines 6-10 and 15-29 to page 13, line 6.

The specification has been amended to indicate that this application claims priority through a chain of applications back to serial number 08/137,821 filed October 15, 1993.

The Examiner's attention is directed to the Information Disclosure Statement included with the application as filed.

Attached hereto is a marked up version of the changes made to the specification by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

CONCLUSION

Early and favorable action is requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for